Key Takeaways:
Midlife, the transitional life stage typically spanning ages 40 to 60, used to be associated with a period of decline, not reinvention. People hitting menopause were sold crisis narratives—hot flashes, weight gain, brain fog—as the beginning of the end. Today, with women living into their 80s and controlling peak household spending power, that story feels structurally dishonest.
But what does midlife mean for women today? Healthspan (years lived well) over lifespan, optimization over endurance, and menopause is starting to be seen as a designed transition, rather than a cliff edge. Beauty and wellness brands marketing to this growing cohort of consumers must pay close attention, or risk speaking to antiquated notions of womanhood.
“The new narrative is ‘there's a scientific basis for your symptoms, and we can [help you] manage it.’ Symptoms improve and so do long-term health outcomes,” Jessica Nazzaro, board-certified obstetrician-gynecologist at the Cleveland Clinic, and medical advisor at Mira, told BeautyMatter.
For Joy Kirst, the founder and CEO at Modern Age Skin, a company creating bioadaptive, science-backed skincare solutions for perimenopausal and menopausal women, the concept was simple. “Not to turn back time for them but meet them where they are and give them a simple routine that supports and improves the skin through the changes they're going through,” she explained to BeautyMatter.
The old midlife script sold blind symptom management for generic menopause templates. The new one sells a personalized, data-driven redesign. As Nazzaro notes, the power shift is already underway. "Women now get to experience individual data and treatment, not blanket one-size-fits-all [advice] and medical treatment."
The Market Opportunity
For the first time in history, women are spending a third of their lives post-menopause. But the messaging is only just catching up.
With global life expectancy averaging at 73.4 years (and women in high-income countries routinely reaching 82-85), this positions ages 40-65 as a third of life, not a sunset phase. And with perimenopause symptoms starting to take place 4-10 years before menopause, marketing that perpetuates a single "change of life" moment is outdated and out of sync with biology.
By 2030, 1.2 billion women will be menopausal or post-menopausal globally, while in the US, roughly 1.3 million women experience menopause each year (typically between the ages of 45-55), yet it's not what they’ve been sold. In a study conducted with the period-tracking app, Flo, researchers at the Mayo Clinic discovered that 71% of 17,494 participants associated perimenopause with hot flashes, yet exhaustion and fatigue were reported more frequently.
Ninety percent of women over 35 experience menopause symptoms that impact their daily life, while 80% of perimenopausal women still lack a basic diagnosis, and untreated symptoms alone are costing an estimated $26.6 billion annually in medical expenses and $1.8 billion in lost productivity in the US.
Women's health and menopause wellness represent a $131 billion opportunity in the US, within a global menopause market valued at $18 billion in 2024 and forecast to reach $27 billion by 2030.
In fact, longevity investment increased 220% to $8.5 billion from 2023 to 2024, and hormone-informed health company Midi Health's $100 million Series D and unicorn status in 2025 signal that menopause care is no longer a niche or taboo—it's infrastructure.
According to McKinsey, the average American loses 14 healthy years between the ages of 51-69 due to preventable conditions, and closing the gap would add $1 trillion to the country’s GDP. Currently, only 7% of femtech startups focus on menopause, leaving the market opportunity vast and largely untapped.
The Paradigm Shift
Menopausal individuals aren't just suffering; they're peak earners with 40+ years ahead, and they deserve cultural narratives that reflect actual modern-day life experiences.
Women 50+ already account for 47% of cosmetics spend, and 43% of US women 45+ are actively seeking menopausal skincare. They demand science-backed solutions, not scented, serenity candles. Case in point: Modern Age Skin, launched in 2023, is designed with women ages 40-80 in mind. It focuses on "anti anti-aging" and product innovation, creating products safe for hormone-fluctuating complexions. "I chose not to use ingredients with hormones or that are hormone-disrupting because [people] in this phase of life can react very differently,” said Kirst.
“Most anti-aging products don't take into account the fluctuations in hormones that occur during perimenopause, which leads to huge swings in hormone levels and menopause, which carries smaller swings but [a greater] depletion of hormones that cause issues with post-menopausal skin,” she added.
Historically, the industry’s response to menopause was damage control. Messaging centered around symptom relief and cosmetic fixes designed to help women feel “less old” while hot flashes were something to “power through.”
But the new framework takes a different approach. Menopause, which is a point in time when a person has gone 12 consecutive months without a menstrual period, is now the entry point to a perimenopause decade: a metabolic, cardiovascular, and cognitive baseline reset. The brain–bone axis replaces the wrinkle count, while systemic resilience replaces symptom suppression. In other words, the same hormonal shifts that reshape the midlife brain also drive the accelerated bone loss that raises risks of osteoporosis and fractures, so menopause is now seen as a whole-body, neuro-skeletal reset rather than a skin-deep aging problem.
Advances in research and technological innovation have led to this shift. Access to large datasets has also enabled analysis of thousands of women across the menopause spectrum: A 2026 study utilizing the UK Biobank database found “widespread associations” between hormonal status and brain architecture.
“When someone can connect a change in sleep, mood, or energy to what’s shifting hormonally, it removes much of the questioning and second-guessing,” Sylvia Kang, CEO and founder at Mira, told BeautyMatter. “Mira aims to help women understand and manage change with greater confidence, rather than feeling like they have to track and interpret everything on their own.”
The San Francisco-based hormonal health company, founded in 2015, recently partnered with the smart ring Oura to connect hormone data with daily health signals, offering women insight into how their sleep, readiness, and temperature trends from Oura directly affect their fluctuations in the Mira app. This collaborative integration demonstrates where the category is heading: from standalone symptom trackers to connected, longitudinal health systems that treat menopause as a decade-long dataset rather than a single event.
Meanwhile, the hormone-responsive skincare sector is growing at 15.9% annually through 2034, as women demand formulations that address cortisol, estrogen decline, and inflammation simultaneously, not separately. Psychodermatology is moving from the fringe to the mainstream, with brands now explicitly targeting the stress–skin axis, cortisol-face prevention, and sleep-disrupted barrier repair. Nutricosmetics are being repositioned, too: Collagen, protein, and nutrient-dense supplements are now being marketed as menopause metabolism support, not vanity products.
And IBSA UK's Hyaluxelle, a non-hormonal injectable for vulvo-vaginal atrophy, signals that treatment options are expanding for women who can't or won't use hormonal therapies.
This shift is grounded in giving those navigating menopause more control, more insight, and more options. But who’s at the forefront of the reframe?
Who's Leading the Reframe
From legacy conglomerates to biotech startups, the industry's biggest players are restructuring their R&D, their partnerships, and their positioning around one idea: that midlife is a longevity inflection point.
L'Oréal has spent 15 years researching longevity, working with 4,000 researchers to create a "Wheel of Longevity for Beauty.” Launched in 2025, the framework tracks 267 biomarkers that influence skin vitality and youthfulness, intending to extend the skin's healthspan. Also in 2025, L’Oréal’s Lancôme brand launched Absolue Longevity Soft Cream, powered by PDRN technology, which is said to augment cellular longevity and metabolism and reverse visible signs of aging. In early 2026, the beauty giant announced the launch of its first longevity‑focused skincare range developed with Swiss biotech brand, Timeline.
OneSkin, the longevity skincare brand founded by four PhD scientists in 2021, set out exclusively to extend the skin’s healthspan. Combining their expertise in skin regeneration, stem cell biology, immunology, and bioinformatics, its female founders worked for five years to develop proprietary peptide OS-01, the first ingredient scientifically proven to target senescent cells, reduce inflammation and collagen breakdown, and reverse the skin’s biological age. Having closed a Series A round in November 2024 and secured a $20 million Series A from Prelude Growth Partners in August 2025, the brand's trajectory shows where investor confidence in longevity skincare currently stands.
Meanwhile, the telehealth companies are focused on messaging and language. Alloy, with $16.3 million in cumulative funding and two commissioned clinical studies, launched its M4 skincare line in July 2025, marketed not as anti-aging but as “menopause performance skincare,” while Hone Health took it further, staging a high-profile “Death To Midlife” campaign in January 2026 that challenged the language of aging itself. Hone Health’s partnership with body-scan brand Prenuvo is the clearest signal yet that the line between beauty, wellness, and preventative medicine is dissolving. It gives members direct access to Prenuvo’s full‑body MRI scans, which typically cost $1,000 to $2,500 per session, while Hone Health positions the results within its hormone and longevity programs.
At the same time, Hone Health is charging $65 for comprehensive hormone lab panels and physician consultations, and its membership model then spreads the cost of ongoing testing and treatment over monthly fees, positioning advanced diagnostics as consumer wellness rather than a medical luxury. Its recent $30 million raise is helping make healthspan solutions accessible to the mainstream.
Cost is one thing. But questions surrounding accessibility remain.
The Access Question
The healthspan rhetoric may be seductive, yet reality remains stratified. With the menopause market projected to represent a $600 billion femtech opportunity by 2030, brands and businesses in this space should question accessibility and affordability, as well as the bottom line.
"Access to women's health has been structurally limited for decades,” Kang explained. “We're realistic about the fact that no single company can solve that entirely—but we can make deliberate choices that lower friction and expand access where we can."
In the UK, National Health Service (NHS) menopause care can see women waiting over a year for diagnosis and hormone replacement therapy (HRT); in the US, 80% of OB-GYN residents report feeling uncomfortable discussing menopause. Alternatively, telehealth platforms are delivering consultations and prescriptions within days, making them an attractive entry point to care—for those who can afford it.
Not only is price–point an issue, but so is ethnicity and sexuality when it comes to care. Everyone born with a uterus will go through menopause, but not all of them are women. When narrow narratives shape policy and care, too many are left to suffer in silence.
According to the North American Menopause Society, 71% of transgender women use or intend to use gender-affirming hormone therapy (GAHT): 25% begin treatment after the age of 40, and 12% begin after age 50. And when they stop treatment, their bodies experience similar symptoms of menopause that cisgender women do due to the estrogen level fluctuations. The misconceptions surrounding trans and non-binary menopause led Tania Glyde, a London-based psychotherapist and counselor who works mainly with clients who identify as gender, sex, and relationship diverse (GSRD), to launch Queer Menopause, a website offering education resources for LGBTQIA+ individuals.
Research from the British Menopause Society and The Study of Women’s Health Across the Nation outlines how hormonal patterns differ between ethnic groups, while minority communities tend to experience more severe symptoms. For example, women of African and Caribbean descent tend to have more intense hot flashes, night sweats, sleep disruption, and mental health issues. In contrast, South Asian women have been found to start menopause much earlier than their Western counterparts. There’s also social and cultural stigma at play, as well as medical misogyny and institutional racism, leaving many people either dismissed or mistreated.
Stella, the UK menopause app, expanded into South Africa via Discovery Health in early 2026, offering free access to roughly 800,000 women ages 35+, signaling insurers' recognition that menopause support is mainstream health infrastructure, not a niche wellness offering.
Awareness is growing, but intrinsic differences demand inclusive solutions.
At the same time, menopause marketing is flooding social media, and concerns over unregulated advice, services, and products are on the rise, so much so that women’s health academics at University College London (UCL) are calling for a national education program to combat the increase in misinformation. The NHS online hospital (launching 2027) is said to prioritize menopause care.
Privacy also acts as a structural access issue, with questions surrounding who owns the data, especially for women in US states with restricted healthcare rights. To combat this, Sonja Rincón launched Menotracker in February 2026. The app, which offers symptom analysis and educational support (available in 177 countries and 41 languages), is built with a privacy-first architecture. Its partnership with the privacy technology company ConsentKeys never stores users’ personal data; therefore, it cannot be sold or shared with third parties.
A 2024 Royal Holloway study of UK menopause tech users found 31% valued community features, but 24% cited misinformation as their top concern, and 93% rated social media data sharing “completely unacceptable,” underscoring why privacy-first tools matter.
Steps are being made in the right direction. But the midlife reframe only works when diagnostics become public health policy, not venture exits.
What This Means for the Beauty Industry
The brands that win this category won’t be the ones that slap “menopause” or “longevity” on a label; they’re the ones rebuilding business models around healthspan as an outcome. Not youthfulness as an aesthetic. Midlife messaging is less about capitalizing on a moment and more about operationalizing a 40‑year relationship with a consumer whose biology, finances, and expectations have all shifted.
For independent beauty and wellness brands, the menopause–meets–longevity space is no longer about clever positioning, but whether you can credibly sit next to medical‑grade diagnostics and still hold up. License or co‑develop biotech‑grade actives and make the path to proof part of the brand story. Commission third‑party clinicals that resonate with both dermatologists and consumers; use subscription models to anchor long‑term protocols rather than auto‑ship moisturizers; and position topical products as pro‑aging and performance‑driven rather than anti-aging—a term Kirst states as “insulting to women.”
Legacy players’ reframing of menopause is more a test of whether existing R&D and retail can be retooled around diagnostics and personalization at scale. The real play is connecting proteomic skin age, lifestyle data, and product responses into closed‑loop systems that update routines as biology changes. Double down on longevity‑focused biotech partnerships and acquisitions that bring in senescence, mitochondrial, or epigenetic capabilities, or look to build in‑store diagnostics and services that sit closer to preventive medicine, like L'Oréal's Cell BioPrint, a five-minute biological age scan released at CEW 2025.
Retailers have the opportunity to create dedicated hubs for longevity and menopause education. From clear organization surrounding symptoms (sleep, cognition, hot flashes, bone density, libido) to curated assortments around clinical backing, research partners, and outcome data, not just “clean,” “natural,” or “hormone‑friendly” claims. Stores can program events and services, such as on‑site scans, lab panels via partners, and menopause‑literate derm consults, turning the space into a healthspan touchpoint.
Done right, the “menopause aisle” disappears, replaced by a healthspan‑first merchandising and messaging that speaks to 40, 60, and 80‑year‑olds as participants in the same long‑term system.
For beauty in general, the end of midlife isn’t semantics—it decides whether the next decade’s hero products sell fear of aging or add tangible healthy years to skin, brain, bones, and life. The only real question for the industry is whether it is willing to kill the decline narrative fast enough to keep up.
Want to continue reading this article and others just like it?
Subscribe to BeautyMatter and access the most current beauty intelligence and news updates.
SubscribeAlready a member, login here.